Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 1
1992 1
1994 1
1995 1
1998 1
2000 1
2002 6
2003 10
2004 3
2005 10
2006 9
2007 11
2008 10
2009 15
2010 6
2011 13
2012 9
2013 5
2014 13
2015 13
2016 11
2017 7
2018 5
2019 5
2020 4
2021 5
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Wang C, Mamza J, Idris I. Wang C, et al. Diabet Med. 2015 May;32(5):585-94. doi: 10.1111/dme.12694. Epub 2015 Feb 13. Diabet Med. 2015. PMID: 25594251 Review.
AIM: We aim to evaluate the effects of biphasic insulin compared with a basal bolus insulin regimen on glycaemic control, total daily insulin requirements, risk of hypoglycaemia, weight and quality of life in patients with diabetes mellitus. ...CONCLUS …
AIM: We aim to evaluate the effects of biphasic insulin compared with a basal bolus insulin regimen on glycaemic contro …
A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT. Rys P, et al. Int J Clin Pract. 2014 Mar;68(3):304-13. doi: 10.1111/ijcp.12337. Epub 2014 Jan 28. Int J Clin Pract. 2014. PMID: 24471814 Review.
OBJECTIVE: It is uncertain whether the addition of biphasic insulin analogues to oral antidiabetic drugs (OADs) is as effective and safe as basal insulin in patients with type 2 diabetes mellitus (T2DM). We performed a systematic review to compare glycaemic c …
OBJECTIVE: It is uncertain whether the addition of biphasic insulin analogues to oral antidiabetic drugs (OADs) is as effectiv …
Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
Onishi Y, Yamada K, Zacho J, Ekelund J, Iwamoto Y. Onishi Y, et al. J Diabetes Investig. 2017 Mar;8(2):210-217. doi: 10.1111/jdi.12569. Epub 2016 Oct 7. J Diabetes Investig. 2017. PMID: 27560769 Free PMC article. Clinical Trial.
AIMS/INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and insulin aspart (30%). ...MATERIALS AND METHODS: In this 6-week, open-label, parallel-group, controlled trial, 66 participants were rando …
AIMS/INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and …
Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W. Yang W, et al. Diabetes Obes Metab. 2019 Jul;21(7):1652-1660. doi: 10.1111/dom.13703. Epub 2019 Apr 4. Diabetes Obes Metab. 2019. PMID: 30869183 Free PMC article. Clinical Trial.
AIMS: To assess the efficacy and safety of twice-daily insulin degludec/insulin aspart (IDegAsp) versus biphasic insulin aspart 30 (BIAsp 30) twice daily, both metformin, in Chinese adults (N = 543) with type 2 diabetes (T2D) inadequately controlled on …
AIMS: To assess the efficacy and safety of twice-daily insulin degludec/insulin aspart (IDegAsp) versus biphasic ins
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
Farmer AJ, Oke J, Stevens R, Holman RR. Farmer AJ, et al. Diabetes Obes Metab. 2011 Dec;13(12):1136-41. doi: 10.1111/j.1463-1326.2011.01475.x. Diabetes Obes Metab. 2011. PMID: 21767341 Clinical Trial.
We further investigated insulin treatment satisfaction between groups. METHODS: Seven hundred and eight patients with suboptimal glycated haemoglobin levels (7.0-10.0%) taking maximally tolerated doses of metformin and sulphonylurea were randomized to biphasic in
We further investigated insulin treatment satisfaction between groups. METHODS: Seven hundred and eight patients with suboptimal glyc …
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses.
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Lasserson DS, et al. Diabetologia. 2009 Oct;52(10):1990-2000. doi: 10.1007/s00125-009-1468-7. Epub 2009 Jul 31. Diabetologia. 2009. PMID: 19644668 Review.
Larger insulin doses at study end were reported in biphasic and prandial arms compared with basal arms. No studies found differences in major hypoglycaemic events, but minor hypoglycaemic events for prandial and biphasic insulin were inconsistently rep …
Larger insulin doses at study end were reported in biphasic and prandial arms compared with basal arms. No studies found diffe …
Bioequivalence of Reference and Biosimilar Preparations of Premixed Biphasic Insulin Aspart: A Comparative Clamp Study.
Dorotenko A, Makarenko I, Karonova T, Protsenko E, Gefen M, Galstyan G, Antonova E, Shitov L, Dzhurko Y, Drai R. Dorotenko A, et al. Clin Pharmacol Drug Dev. 2023 Dec;12(12):1178-1184. doi: 10.1002/cpdd.1333. Epub 2023 Sep 20. Clin Pharmacol Drug Dev. 2023. PMID: 37728234 Clinical Trial.
Biphasic insulin aspart 30 is a premixed formulation containing a soluble fraction of insulin aspart (30%) and a protamine-crystallized fraction (70%) that was developed to combine the rapid-acting and prolonged advantages of commercially available insulin
Biphasic insulin aspart 30 is a premixed formulation containing a soluble fraction of insulin aspart (30%) and a protam
Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
Schmoelzer I, de Campo A, Pressl H, Stelzl H, Dittrich P, Oettl K, Wascher TC. Schmoelzer I, et al. Exp Clin Endocrinol Diabetes. 2005 Mar;113(3):176-81. doi: 10.1055/s-2005-837521. Exp Clin Endocrinol Diabetes. 2005. PMID: 15789278 Clinical Trial.
BACKGROUND: Premixed insulin analogues reduce postprandial hyperglycemia in patients with Type 2 diabetes in comparison to premixed regular insulin. ...MATERIALS AND METHODS: 12 subjects (3 men; age 59 +/- 5 years; BMI 30.5 +/- 5.9 kg/m2, duration of diabetes 9 +/- …
BACKGROUND: Premixed insulin analogues reduce postprandial hyperglycemia in patients with Type 2 diabetes in comparison to premixed r …
Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S. Hermansen K, et al. Diabetes Care. 2002 May;25(5):883-8. doi: 10.2337/diacare.25.5.883. Diabetes Care. 2002. PMID: 11978685 Clinical Trial.
OBJECTIVE: The rapid-acting insulin analogs aspart and lispro have now been developed in biphasic formulations. This trial compared the postprandial serum glucose control of biphasic insulin aspart 30 (BIAsp 30: 30% aspart, 70% protaminated aspart) wit …
OBJECTIVE: The rapid-acting insulin analogs aspart and lispro have now been developed in biphasic formulations. This trial com …
Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.
Hassanein M, Echtay AS, Malek R, Omar M, Shaikh SS, Ekelund M, Kaplan K, Kamaruddin NA. Hassanein M, et al. Diabetes Res Clin Pract. 2018 Jan;135:218-226. doi: 10.1016/j.diabres.2017.11.027. Epub 2017 Nov 26. Diabetes Res Clin Pract. 2018. PMID: 29183844 Free article. Clinical Trial.
AIMS: To compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) before, during and after Ramadan in patients with type 2 diabetes mellitus (T2DM) who fasted during Ramadan. ...CONCLUSIONS: …
AIMS: To compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspar …
159 results